Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation

Craig J. Burd, Christin E. Petre, Lisa M. Morey, Ying Wang, Monica P. Revelo, Christopher A. Haiman, Shan Lu, Cecilia M. Fenoglio-Preiser, Jiwen Li, Erik S. Knudsen, Jiemin Wong, Karen E. Knudsen

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Cyclin D1 is a multifaceted regulator of both transcription and cell-cycle progression that exists in two distinct isoforms, cyclin D1a and D1b. In the prostate, cyclin D1a acts through discrete mechanisms to negatively regulate androgen receptor (AR) activity and thus limit androgen-dependent proliferation. Accordingly, cyclin D1a is rarely overexpressed in prostatic adenocarcinoma and holds little prognostic value in this tumor type. However, a common polymorphism (A870) known to facilitate production of cyclin D1b is associated with increased prostate cancer risk. Here we show that cyclin D1b is expressed at high frequency in prostate cancer and is up-regulated in neoplastic disease. Furthermore, our data demonstrate that, although cyclin D1b retains AR association, it is selectively compromised for AR regulation. The altered ability of cyclin D1b to regulate the AR was observed by using both in vitro and in vivo assays and was associated with compromised regulation of AR-dependent proliferation. Consistent with previous reports, expression of cyclin D1a inhibited cell-cycle progression in AR-dependent prostate cancer cells. Strikingly, cyclin D1b significantly stimulated proliferation in this cell type. AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells. In summary, these studies indicate that the altered AR regulatory capacity of cyclin D1b contributes to its association with increased prostate cancer risk and provide evidence of cyclin D1b-mediated transcriptional regulation.

Original languageEnglish (US)
Pages (from-to)2190-2195
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number7
DOIs
StatePublished - Feb 14 2006

Fingerprint

Cyclins
Androgen Receptors
Prostatic Neoplasms
Growth
Cyclin D1
Cell Cycle
Co-Repressor Proteins
Androgens
Prostate
Protein Isoforms
Adenocarcinoma
Cell Proliferation

Keywords

  • Cell cycle
  • Corepressor
  • G870A
  • Polymorphism
  • Thyroid hormone receptor β

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. / Burd, Craig J.; Petre, Christin E.; Morey, Lisa M.; Wang, Ying; Revelo, Monica P.; Haiman, Christopher A.; Lu, Shan; Fenoglio-Preiser, Cecilia M.; Li, Jiwen; Knudsen, Erik S.; Wong, Jiemin; Knudsen, Karen E.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 7, 14.02.2006, p. 2190-2195.

Research output: Contribution to journalArticle

Burd, CJ, Petre, CE, Morey, LM, Wang, Y, Revelo, MP, Haiman, CA, Lu, S, Fenoglio-Preiser, CM, Li, J, Knudsen, ES, Wong, J & Knudsen, KE 2006, 'Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation', Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2190-2195. https://doi.org/10.1073/pnas.0506281103
Burd, Craig J. ; Petre, Christin E. ; Morey, Lisa M. ; Wang, Ying ; Revelo, Monica P. ; Haiman, Christopher A. ; Lu, Shan ; Fenoglio-Preiser, Cecilia M. ; Li, Jiwen ; Knudsen, Erik S. ; Wong, Jiemin ; Knudsen, Karen E. / Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 7. pp. 2190-2195.
@article{5949d7af8fe74bcb8ff99cd96e0cc044,
title = "Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation",
abstract = "Cyclin D1 is a multifaceted regulator of both transcription and cell-cycle progression that exists in two distinct isoforms, cyclin D1a and D1b. In the prostate, cyclin D1a acts through discrete mechanisms to negatively regulate androgen receptor (AR) activity and thus limit androgen-dependent proliferation. Accordingly, cyclin D1a is rarely overexpressed in prostatic adenocarcinoma and holds little prognostic value in this tumor type. However, a common polymorphism (A870) known to facilitate production of cyclin D1b is associated with increased prostate cancer risk. Here we show that cyclin D1b is expressed at high frequency in prostate cancer and is up-regulated in neoplastic disease. Furthermore, our data demonstrate that, although cyclin D1b retains AR association, it is selectively compromised for AR regulation. The altered ability of cyclin D1b to regulate the AR was observed by using both in vitro and in vivo assays and was associated with compromised regulation of AR-dependent proliferation. Consistent with previous reports, expression of cyclin D1a inhibited cell-cycle progression in AR-dependent prostate cancer cells. Strikingly, cyclin D1b significantly stimulated proliferation in this cell type. AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells. In summary, these studies indicate that the altered AR regulatory capacity of cyclin D1b contributes to its association with increased prostate cancer risk and provide evidence of cyclin D1b-mediated transcriptional regulation.",
keywords = "Cell cycle, Corepressor, G870A, Polymorphism, Thyroid hormone receptor β",
author = "Burd, {Craig J.} and Petre, {Christin E.} and Morey, {Lisa M.} and Ying Wang and Revelo, {Monica P.} and Haiman, {Christopher A.} and Shan Lu and Fenoglio-Preiser, {Cecilia M.} and Jiwen Li and Knudsen, {Erik S.} and Jiemin Wong and Knudsen, {Karen E.}",
year = "2006",
month = "2",
day = "14",
doi = "10.1073/pnas.0506281103",
language = "English (US)",
volume = "103",
pages = "2190--2195",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation

AU - Burd, Craig J.

AU - Petre, Christin E.

AU - Morey, Lisa M.

AU - Wang, Ying

AU - Revelo, Monica P.

AU - Haiman, Christopher A.

AU - Lu, Shan

AU - Fenoglio-Preiser, Cecilia M.

AU - Li, Jiwen

AU - Knudsen, Erik S.

AU - Wong, Jiemin

AU - Knudsen, Karen E.

PY - 2006/2/14

Y1 - 2006/2/14

N2 - Cyclin D1 is a multifaceted regulator of both transcription and cell-cycle progression that exists in two distinct isoforms, cyclin D1a and D1b. In the prostate, cyclin D1a acts through discrete mechanisms to negatively regulate androgen receptor (AR) activity and thus limit androgen-dependent proliferation. Accordingly, cyclin D1a is rarely overexpressed in prostatic adenocarcinoma and holds little prognostic value in this tumor type. However, a common polymorphism (A870) known to facilitate production of cyclin D1b is associated with increased prostate cancer risk. Here we show that cyclin D1b is expressed at high frequency in prostate cancer and is up-regulated in neoplastic disease. Furthermore, our data demonstrate that, although cyclin D1b retains AR association, it is selectively compromised for AR regulation. The altered ability of cyclin D1b to regulate the AR was observed by using both in vitro and in vivo assays and was associated with compromised regulation of AR-dependent proliferation. Consistent with previous reports, expression of cyclin D1a inhibited cell-cycle progression in AR-dependent prostate cancer cells. Strikingly, cyclin D1b significantly stimulated proliferation in this cell type. AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells. In summary, these studies indicate that the altered AR regulatory capacity of cyclin D1b contributes to its association with increased prostate cancer risk and provide evidence of cyclin D1b-mediated transcriptional regulation.

AB - Cyclin D1 is a multifaceted regulator of both transcription and cell-cycle progression that exists in two distinct isoforms, cyclin D1a and D1b. In the prostate, cyclin D1a acts through discrete mechanisms to negatively regulate androgen receptor (AR) activity and thus limit androgen-dependent proliferation. Accordingly, cyclin D1a is rarely overexpressed in prostatic adenocarcinoma and holds little prognostic value in this tumor type. However, a common polymorphism (A870) known to facilitate production of cyclin D1b is associated with increased prostate cancer risk. Here we show that cyclin D1b is expressed at high frequency in prostate cancer and is up-regulated in neoplastic disease. Furthermore, our data demonstrate that, although cyclin D1b retains AR association, it is selectively compromised for AR regulation. The altered ability of cyclin D1b to regulate the AR was observed by using both in vitro and in vivo assays and was associated with compromised regulation of AR-dependent proliferation. Consistent with previous reports, expression of cyclin D1a inhibited cell-cycle progression in AR-dependent prostate cancer cells. Strikingly, cyclin D1b significantly stimulated proliferation in this cell type. AR-negative prostate cancer cells were nonresponsive to cyclin D1 (a or b) expression, indicating that defects in AR corepressor function yield a growth advantage specifically in AR-dependent cells. In summary, these studies indicate that the altered AR regulatory capacity of cyclin D1b contributes to its association with increased prostate cancer risk and provide evidence of cyclin D1b-mediated transcriptional regulation.

KW - Cell cycle

KW - Corepressor

KW - G870A

KW - Polymorphism

KW - Thyroid hormone receptor β

UR - http://www.scopus.com/inward/record.url?scp=33144474074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144474074&partnerID=8YFLogxK

U2 - 10.1073/pnas.0506281103

DO - 10.1073/pnas.0506281103

M3 - Article

C2 - 16461912

AN - SCOPUS:33144474074

VL - 103

SP - 2190

EP - 2195

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -